• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Study Purpose

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1.
  • - At least 1 lesion accessible for biopsy.
  • - Eastern Cooperative Oncology Group Performance Status of 0 or 1.

Exclusion Criteria:

  • - Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll) - Participants with active, known or suspected autoimmune disease.
  • - Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration.
  • - Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS) - Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy.
Other protocol defined inclusion/exclusion criteria could apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03400332
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Bristol-Myers Squibb
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Australia, Belgium, Canada, France, Germany, Italy, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cancer, Melanoma
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Part 1A: BMS-986253 + nivolumab

Experimental: Part 1B: BMS-986253 + nivolumab

Experimental: Part 1C: BMS-986253 + nivolumab + ipilimumab

Experimental: Part 2A: BMS-986253 + nivolumab + ipilimumab

Placebo Comparator: Part 2B: Placebo + nivolumab + ipilimumab

Interventions

Drug: - BMS-986253

Specified dose on specified days

Biological: - Nivolumab

Specified dose on specified days

Biological: - Ipilimumab

Specified dose on specified days

Other: - Placebo

Specified dose on specified days

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Local Institution - 0059, Springdale, Arkansas

Status

Address

Local Institution - 0059

Springdale, Arkansas, 72762

Local Institution - 0099, Los Angeles, California

Status

Address

Local Institution - 0099

Los Angeles, California, 90033

Local Institution - 0007, Lakewood, Colorado

Status

Address

Local Institution - 0007

Lakewood, Colorado, 80228

Local Institution - 0087, Atlanta, Georgia

Status

Address

Local Institution - 0087

Atlanta, Georgia, 30322

Local Institution - 0100, Atlanta, Georgia

Status

Address

Local Institution - 0100

Atlanta, Georgia, 30342

Local Institution - 0101, Marietta, Georgia

Status

Address

Local Institution - 0101

Marietta, Georgia, 30060

Local Institution - 0012, Columbia, Maryland

Status

Address

Local Institution - 0012

Columbia, Maryland, 21044

Local Institution - 0003, Lutherville, Maryland

Status

Address

Local Institution - 0003

Lutherville, Maryland, 21093

Local Institution - 0060, Boston, Massachusetts

Status

Address

Local Institution - 0060

Boston, Massachusetts, 02215

Local Institution - 0004, Ann Arbor, Michigan

Status

Address

Local Institution - 0004

Ann Arbor, Michigan, 48109

Local Institution - 0076, Omaha, Nebraska

Status

Address

Local Institution - 0076

Omaha, Nebraska, 68130

Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada

Status

Address

Comprehensive Cancer Centers Of Nevada

Las Vegas, Nevada, 89169

Local Institution - 0005, Hackensack, New Jersey

Status

Address

Local Institution - 0005

Hackensack, New Jersey, 07601

Local Institution - 0032, New Brunswick, New Jersey

Status

Address

Local Institution - 0032

New Brunswick, New Jersey, 08903

Local Institution - 0025, New York, New York

Status

Address

Local Institution - 0025

New York, New York, 10029

Local Institution - 0002, New York, New York

Status

Address

Local Institution - 0002

New York, New York, 10032

Local Institution - 0028, Oklahoma City, Oklahoma

Status

Address

Local Institution - 0028

Oklahoma City, Oklahoma, 73104

Local Institution - 0017, Eugene, Oregon

Status

Address

Local Institution - 0017

Eugene, Oregon, 97401

Local Institution - 0001, Pittsburgh, Pennsylvania

Status

Address

Local Institution - 0001

Pittsburgh, Pennsylvania, 15213

Local Institution - 0009, Greenville, South Carolina

Status

Address

Local Institution - 0009

Greenville, South Carolina, 29615

Local Institution - 0011, Austin, Texas

Status

Address

Local Institution - 0011

Austin, Texas, 78705

Local Institution - 0010, Dallas, Texas

Status

Address

Local Institution - 0010

Dallas, Texas, 75246

Local Institution - 0014, Fort Worth, Texas

Status

Address

Local Institution - 0014

Fort Worth, Texas, 76104-3927

Local Institution - 0018, Houston, Texas

Status

Address

Local Institution - 0018

Houston, Texas, 77030

Local Institution - 0006, San Antonio, Texas

Status

Address

Local Institution - 0006

San Antonio, Texas, 78240

Local Institution - 0013, Tyler, Texas

Status

Address

Local Institution - 0013

Tyler, Texas, 75702

Local Institution - 0058, Salt Lake City, Utah

Status

Address

Local Institution - 0058

Salt Lake City, Utah, 84112

Local Institution - 0015, Fairfax, Virginia

Status

Address

Local Institution - 0015

Fairfax, Virginia, 22031

Local Institution - 0008, Norfolk, Virginia

Status

Address

Local Institution - 0008

Norfolk, Virginia, 23502

International Sites

Local Institution - 0088, Wollstonecraft, New South Wales, Australia

Status

Address

Local Institution - 0088

Wollstonecraft, New South Wales, 2065

Local Institution - 0096, Adelaide, South Australia, Australia

Status

Address

Local Institution - 0096

Adelaide, South Australia, 5000

Local Institution - 0090, Melbourne, Victoria, Australia

Status

Address

Local Institution - 0090

Melbourne, Victoria, 3000

Local Institution - 0095, Melbourne, Victoria, Australia

Status

Address

Local Institution - 0095

Melbourne, Victoria, 3004

Local Institution - 0097, Perth, Western Australia, Australia

Status

Address

Local Institution - 0097

Perth, Western Australia, 6009

Local Institution - 0091, Ballarat Central, Australia

Status

Address

Local Institution - 0091

Ballarat Central, , VIC 3350

Local Institution - 0037, Bruxelles, Belgium

Status

Address

Local Institution - 0037

Bruxelles, , 1200

Local Institution - 0036, Gent, Belgium

Status

Address

Local Institution - 0036

Gent, , 9000

Local Institution - 0082, Kortrijk, Belgium

Status

Address

Local Institution - 0082

Kortrijk, , 8500

Local Institution - 0030, Edmonton, Alberta, Canada

Status

Address

Local Institution - 0030

Edmonton, Alberta, T6G 1Z2

Local Institution - 0029, Vancouver, British Columbia, Canada

Status

Address

Local Institution - 0029

Vancouver, British Columbia, V5Z 4E6

Local Institution - 0078, Victoria, British Columbia, Canada

Status

Address

Local Institution - 0078

Victoria, British Columbia, V8R 6V5

Local Institution - 0020, Toronto, Ontario, Canada

Status

Address

Local Institution - 0020

Toronto, Ontario, M5G 1Z5

Local Institution - 0055, Toronto, Ontario, Canada

Status

Address

Local Institution - 0055

Toronto, Ontario, M5G 2M9

Local Institution - 0056, Montréal, Quebec, Canada

Status

Address

Local Institution - 0056

Montréal, Quebec, H2X 0A9

Local Institution - 0067, Marseille, Bouches-du-Rhône, France

Status

Address

Local Institution - 0067

Marseille, Bouches-du-Rhône, 13385

Local Institution - 0085, Nantes, France

Status

Address

Local Institution - 0085

Nantes, , 44000

Local Institution - 0068, Paris, France

Status

Address

Local Institution - 0068

Paris, , 75010

Local Institution - 0102, Toulouse, France

Status

Address

Local Institution - 0102

Toulouse, , 31059

Local Institution - 0069, Villejuif, France

Status

Address

Local Institution - 0069

Villejuif, , 94800

Local Institution - 0054, Tübingen, Baden-Württemberg, Germany

Status

Address

Local Institution - 0054

Tübingen, Baden-Württemberg, 72076

Local Institution - 0052, Mainz, Rheinland-Pfalz, Germany

Status

Address

Local Institution - 0052

Mainz, Rheinland-Pfalz, 55131

Local Institution - 0034, Berlin, Germany

Status

Address

Local Institution - 0034

Berlin, , 12200

Local Institution - 0053, Hamburg, Germany

Status

Address

Local Institution - 0053

Hamburg, , 20251

Local Institution - 0043, Forlì, Italy

Status

Address

Local Institution - 0043

Forlì, , 47014

Local Institution - 0042, Milano, Italy

Status

Address

Local Institution - 0042

Milano, , 20132

Local Institution - 0027, Napoli, Italy

Status

Address

Local Institution - 0027

Napoli, , 80131

Local Institution - 0026, Rozzano-milano, Italy

Status

Address

Local Institution - 0026

Rozzano-milano, , 20089

Local Institution - 0071, Krakow, Poland

Status

Address

Local Institution - 0071

Krakow, , 31-115

Local Institution - 0077, Warszawa, Poland

Status

Address

Local Institution - 0077

Warszawa, , 02-781

Local Institution - 0045, Madrid, Spain

Status

Address

Local Institution - 0045

Madrid, , 28034

Local Institution - 0022, Madrid, Spain

Status

Address

Local Institution - 0022

Madrid, , 28040

Local Institution - 0023, Madrid, Spain

Status

Address

Local Institution - 0023

Madrid, , 28050

Local Institution - 0044, Malaga, Spain

Status

Address

Local Institution - 0044

Malaga, , 29010

Local Institution - 0021, Pamplona, Spain

Status

Address

Local Institution - 0021

Pamplona, , 31008

Local Institution - 0047, Santiago de Compostela, Spain

Status

Address

Local Institution - 0047

Santiago de Compostela, , 15706

Local Institution - 0049, Lund, Sweden

Status

Address

Local Institution - 0049

Lund, , 221 85

Local Institution - 0040, Lausanne, Switzerland

Status

Address

Local Institution - 0040

Lausanne, , 1011

Local Institution - 0041, St.Gallen, Switzerland

Status

Address

Local Institution - 0041

St.Gallen, , 9007

Local Institution - 0039, Zuerich, Switzerland

Status

Address

Local Institution - 0039

Zuerich, , 8091

Local Institution - 0024, Manchester, Greater Manchester, United Kingdom

Status

Address

Local Institution - 0024

Manchester, Greater Manchester, M20 4BX

Local Institution - 0083, Glasgow, Lanarkshire, United Kingdom

Status

Address

Local Institution - 0083

Glasgow, Lanarkshire, G12 0YN

Local Institution - 0019, Birmingham, West Midlands, United Kingdom

Status

Address

Local Institution - 0019

Birmingham, West Midlands, B15 2TH

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact